The prescription rates for CCBs in patients with heart failure (12 out of 527 patient, or 2.3%), beta-blockers in asthma/COPD patients (83 out of 882 patients, or 9.4%), and alpha-1-blockers in patients with renal insufficiency (1 out of 20 patients, or 5.0%) - all of which are contraindicated in the respective patient group - were below 10%. This evidence concerns the gene PSMA6 and Renal insufficiency.